Texas Children's Cancer and Hematology Center A Study of the Safety and Tolerability in Participants with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated with Miransertib (MK-7075) in Other Studies (MK-7075-006)

This Phase 2 study evaluates the targeted medicine miransertib in children and adults with PROS or Proteus Syndrome.

Description

PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) are rare conditions caused by genetic mutations that lead to abnormal tissue growth. Miransertib is an investigational drug that targets a specific pathway involved in this overgrowth. This study aims to understand the long-term safety and effects of miransertib in patients with vascular malformations caused by these genetic mutations. By continuing to monitor these individuals, researchers hope to gather more information about how the drug works over time and whether it continues to provide benefits. This study does not involve new participants but follows those already treated with miransertib.

Eligibility

• Ages 2 to 120 years
• Diagnosed with PROS or Proteus Syndrome
• Previously or currently enrolled in a miransertib study

Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov